{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-027823","form_type":"8-K","ticker":"MNOV","cik":"0001226616","company_name":"MEDICINOVA INC","filed_at":"2023-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.191433+00:00","generated_at":"2026-06-14T00:55:22.477567+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Stockholders elect director, ratify auditor, approve 2023 equity plan","bullets":["Hideki Nagao elected Class I director with 19.7M for, 7.5M against, 1.4M abstain, 2.7M broker non-vote.","BDO USA, LLP ratified as independent auditor for fiscal 2023: 27.8M for, 2.4M against, 1.1M abstain.","2023 Equity Incentive Plan approved: 19.2M for, 7.9M against, 1.5M abstain, 2.7M broker non-vote.","Meeting held June 13, 2023; 31.3M shares voted of 49.0M outstanding (quorum present)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-027823","json":"https://secwatch.observer/filing/0000950170-23-027823.json","markdown":"https://secwatch.observer/filing/0000950170-23-027823.md","text":"https://secwatch.observer/filing/0000950170-23-027823.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1226616/000095017023027823/0000950170-23-027823-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1226616/000095017023027823/mnov-20230613.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T00:55:22.477567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3e920127741d55a581a14559cb4b711f4d99acb7","claim":"MEDICINOVA INC shareholders approved Approve the Company’s 2023 Equity Incentive Plan, as disclosed in the Proxy Statement. at the 2023-06-13 meeting.","evidence_excerpt":"To approve the Company’s 2023 Equity Incentive Plan, as disclosed in the Proxy Statement. This proposal was approved, with the votes thereon at the Annual Meeting as follows: Final Voting Results For Against Abstain Broker Non-Vote 19,200,437 7,879,289 1,504,082 2,715,513","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1226616/000095017023027823/0000950170-23-027823-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"7eed077f5c7ffb4493bfb8a762a2c6ce32cc0dcc","claim":"MEDICINOVA INC shareholders approved Ratify the selection of BDO USA, LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. at the 2023-06-13 meeting.","evidence_excerpt":"To ratify the selection of BDO USA, LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. This proposal was approved, with the votes thereon at the Annual Meeting as follows: Final Voting Results For Against Abstain Broker Non-Vote 27,807,178 2,362,900 1,129,243 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1226616/000095017023027823/0000950170-23-027823-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"bcec80a2880418b5e1a1b31498de95ee0617d767","claim":"MEDICINOVA INC shareholders approved Election of one Class I Director nominee named below to serve until the 2026 Annual Meeting of stockholders and until their successors have been duly elected and qualified, or, if sooner, until their earlier death, resignation or removal. at the 2023-06-13 meeting.","evidence_excerpt":"To elect one Class I Director nominee named below to serve until the 2026 Annual Meeting of stockholders and until their successors have been duly elected and qualified, or, if sooner, until their earlier death, resignation or removal. The named nominee was so elected, with the votes thereon at the Annual Meeting as follows: Final Voting Results Nominees For Against Abstain Broker Non-Vote Hideki Nagao 19,685,986 7,517,392 1,380,430 2,715,513","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1226616/000095017023027823/0000950170-23-027823-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}